Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Position Lifted by Braidwell LP

Braidwell LP boosted its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 144.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,206,589 shares of the company's stock after purchasing an additional 712,902 shares during the quarter. Braidwell LP owned about 4.08% of Dianthus Therapeutics worth $26,304,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. R Squared Ltd acquired a new stake in Dianthus Therapeutics during the 4th quarter worth $26,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Dianthus Therapeutics during the fourth quarter worth about $33,000. KBC Group NV acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at about $35,000. BNP Paribas Financial Markets purchased a new position in Dianthus Therapeutics during the 4th quarter worth approximately $59,000. Finally, AlphaQuest LLC lifted its stake in Dianthus Therapeutics by 273.1% in the fourth quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock valued at $91,000 after buying an additional 3,072 shares during the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Trading Down 5.0 %

Shares of DNTH traded down $1.03 during mid-day trading on Friday, reaching $19.59. The company had a trading volume of 209,703 shares, compared to its average volume of 267,417. Dianthus Therapeutics, Inc. has a fifty-two week low of $13.37 and a fifty-two week high of $32.27. The firm has a fifty day simple moving average of $19.83 and a 200-day simple moving average of $22.41. The stock has a market cap of $629.35 million, a price-to-earnings ratio of -7.84 and a beta of 1.48.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.04. The company had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. As a group, equities analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Wedbush reissued an "outperform" rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Guggenheim reiterated a "buy" rating and set a $84.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Dianthus Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $54.33.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.